Page last updated: 2024-08-23

valrubicin and Carcinoma, Transitional Cell

valrubicin has been researched along with Carcinoma, Transitional Cell in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kamat, AM; Li, R; Spiess, PE1
Barlow, LJ; Benson, MC1
Bahnson, RR; Bamberger, MH; Bellingham, C; Childs, SJ; Edson, M; Giantonio, B; Greenberg, RE; Israel, M; O'Dwyer, PJ; Steinberg, GD; Sweatman, T; Wood, D1
Baselli, EC; Greenberg, RE1
Hetherington, J; Kisbenedek, L; Newling, DW; Robinson, MR; Sundaram, SK1
Luciani, LG; Murphy, WM; Neulander, E; Wajsman, Z1
Alsikafi, NF; Kuznetsov, DD; O'Connor, RC; Steinberg, GD1

Reviews

3 review(s) available for valrubicin and Carcinoma, Transitional Cell

ArticleYear
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
    Current urology reports, 2013, Volume: 14, Issue:2

    Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms

2013
Intravesical therapy for superficial bladder cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms

2000
Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:6

    Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Guidelines as Topic; Humans; Molecular Structure; Urinary Bladder Neoplasms

2001

Trials

2 trial(s) available for valrubicin and Carcinoma, Transitional Cell

ArticleYear
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.
    Urology, 1997, Volume: 49, Issue:3

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anthracyclines; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms

1997
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.
    European urology, 2001, Volume: 39, Issue:6

    Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms

2001

Other Studies

2 other study(ies) available for valrubicin and Carcinoma, Transitional Cell

ArticleYear
Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?
    European urology, 2018, Volume: 74, Issue:4

    Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms

2018
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Urology, 2001, Volume: 58, Issue:3

    Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Doxorubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Treatment Outcome; Urinary Bladder Neoplasms

2001